

Research Article

Neospora caninum SRS2 Protein: Essential Vaccination Targets and Biochemical Features for Next-Generation Vaccine Design

Ali Asghari ¹, Bahareh Kordi,² Bahman Maleki,³ Hamidreza Majidani ²,
Morteza Shams ⁴ and Razi Naserifar ⁴

¹Department of Medical Parasitology and Mycology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

²Department of Basic Medical Sciences, Neyshabur University of Medical Sciences, Neyshabur, Iran

³Department of Parasitology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran

⁴Zoonotic Diseases Research Center, Ilam University of Medical Sciences, Ilam, Iran

Correspondence should be addressed to Morteza Shams; shamsimorteza55@gmail.com

Received 20 September 2021; Accepted 23 March 2022; Published 6 April 2022

Academic Editor: Jane Hanrahan

Copyright © 2022 Ali Asghari et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Vaccination is a standout preventive measure to combat neosporosis among cattle herds. The present *in silico* study was done to evaluate the physicochemical properties and potent immunogenic epitopes of *N. caninum* SRS2 protein as a possible vaccine candidate. Web-based tools were used to predict physicochemical properties, antigenicity, allergenicity, solubility, posttranslational modification (PTM) sites, transmembrane domains and signal peptide, and secondary and tertiary structures as well as intrinsically disordered regions, followed by identification and screening of potential linear and conformational B-cell epitopes and those peptides having affinity to bind mouse major histocompatibility complex (MHC) and cytotoxic T lymphocyte (CTL). The protein had 401 residues with a molecular weight of 42 kDa, representing aliphatic index of 69.35 (thermotolerant) and GRAVY score of -0.294 (hydrophilic). There were 53 PTM sites without a signal peptide in the sequence. Secondary structure comprised mostly by extended strand, followed by helices and coils. The Ramachandran plot of the refined model showed 90.2%, 8.8%, 0.5%, and 0.5% residues in the favored, additional allowed, generously allowed, and disallowed regions, correspondingly. Additionally, various potential B-cell (linear and conformational), CTL, and MHC-binding epitopes were predicted for *N. caninum* SRS2. These epitopes could be further utilized in the multiepitope vaccine constructs directed against neosporosis.

1. Introduction

Neosporosis is a parasitic disease caused by an intracellular apicomplexan, *Neospora caninum* (*N. caninum*) ([1]), with serious sequelae such as reproductive failure in livestock species, particularly in cows [2, 3]. This protozoan also infects rodents, wild ungulates, birds, and marine mammals [4]. The parasite employs two hosts to complete its life cycle, so that dog (*Canis familiaris*) [5], dingo (*Canis dingo*) [6], coyote (*Canis latrans*) [7], and gray wolf (*Canis lupus*) [8] are definitive hosts, while cattle and buffalo are the most important intermediate hosts [9]. The parasite possesses three distinct infective stages, comprising tachyzoite (acute infection), bradyzoite (chronic infection), and sporozoite (environmental contamination) [10]. Infected canids contaminate the envi-

ronment through oocyst shedding, being infectious for both canids and herbivores [11]. The parasite is maintained within cattle populations through transplacental transmission, resulting from oocyst ingestion (exogenously) and/or reactivated infection during gestation (endogenously) [12, 13]. In addition to the endemic and/or epidemic abortions in midgestation, there are other factors that economically impact the cattle industry including reduced weight gain in beef calves, decreased milk yield [10], replacing culled animals [14], and the additional costs of veterinary care [15].

Ordinarily, various strategies are proposed to cattle producers in order to reduce infections within herds, including the following: (i) identify and cull infected animals in case of endemic abortions, (ii) prevention of contact between cattle and definitive hosts, hence reducing oocyst contamination,

in case of epidemic abortions, (iii) chemotherapy of seropositive animals, and (iv) vaccination protocols [16]. Lack of effective, safe drugs on the one hand and long-time treatment causing the issue of drug residues in food animals on the other hand make treatment troublesome economically [14, 17]. Despite over a decade of research on immunization against *N. caninum* using various protocols, no commercial vaccine has been developed so far [18]. An ideal vaccination against *N. caninum* may comply with several issues, encompassing a considerable decline in oocyst shedding by final hosts, reduction of tissue cysts in food animals to avoid transmission via carnivorous, and confining tachyzoite multiplication in pregnant cow to lower the rate of transplacental transmission [16]. Accordingly, such vaccine candidate should stimulate both mucosal and systemic cell-mediated and antibody-dependent components [19]. Thus far, several vaccination strategies using naturally less-virulent isolates and/or attenuated strains have been exploited in cattle and mouse models, showing to be efficacious in spite of safety concerns and production costs [10]. Subunit peptide-based or DNA vaccines are more deeply investigated due to their evident benefits in reduced production, processing, and storage costs along with higher shelf-life and stability [20]. Mostly, those molecules involved in adhesion/invasion processes such as surface antigens (SAGs), microneme (MIC), and rhoptry (ROP) proteins, dense granular (GRA) components, and targets in parasitophorous vacuole membrane (PVM) have been targeted in subunit vaccines [21].

Immunoinformatics is an emerging computer-aided practice for a rational, structure-based vaccine design in a time- and cost-effective manner, which also optimizes biochemical and immunogenic performances [22]. Immunodominant tachyzoite-specific surface antigens such as *N. caninum* SAG1-related sequence 2 (NcSRS2) have been shown as one of the promising vaccine candidates in murine models, providing protection against lethal challenge or vertical transmission [23–25]. Nevertheless, lack of information on NcSRS2 biochemical features and potential immunogenic epitopes in mouse models directed us to conduct the present *in silico* study.

2. Methods

2.1. NcSRS2 Protein Sequence Retrieval. The amino acid sequence of the NcSRS2 protein was retrieved through the UniProtKB database, available at <https://www.uniprot.org/>, under accession number of Q58L77.

2.2. Prediction of Antigenicity, Allergenicity, Solubility, and Physicochemical Characteristics. Antigenicity is a principal characteristic of a vaccine candidate and was evaluated using two web servers: ANTIGENpro (<http://scratch.proteomics.ics.uci.edu/>) and VaxiJen v2.0 (<http://www.ddgpharmfac.net/vaxijen/>). The latter is a freely accessible server which predicts on the basis of physicochemical properties of a protein and turns sequences into uniform vectors via auto cross covariance (ACC) approach [26, 27]. Also, ANTIGENpro is a pathogen-independent, alignment-free predictor of antigenicity using a two-stage architecture and five ML algorithms, trained by

reactivity information obtained from protein microarray analyses for five pathogens [28]. Three web servers predicted allergenicity, including AlgPred (<http://crdd.osdd.net/raghava/algpred/>), AllergenFP v1.0 (<https://ddgpharmfac.net/AllergenFP/>), and AllerTOP v2.0 (<http://www.ddg-pharmfac.net/AllerTOP>). An alignment-free approach with the Matthews correlation coefficient of 0.759 is employed by AllergenFP v1.0 server [29, 30], while AllerTOP v2.0 exploits several machine learning methods, comprising k-nearest neighbors, cross-variance transformation, and E-descriptors [31]. Moreover, mapping IgE epitopes, MEME (Multiple Em for Motif Elicitation)/MAST (Motif Alignment and Search Tool) allergen motifs were utilized by AlgPred web server to predict allergens [32]. Protein-Sol web server, available at <https://proteinsol.manchester.ac.uk/>, predicted solubility of NcSRS2 with a threshold score of 0.45 as the population average of the experimental dataset, so higher scores indicate higher protein solubility [33]. Finally, ExpASy ProtParam server (<https://web.expasy.org/protparam/>) was used to estimate some important physicochemical properties of NcSRS2 such as molecular weight (MW), number of negatively and positively charged residues, aliphatic and instability indices, isoelectric point (pI), half-life, and grand average of hydrophobicity (GRAVY) [34, 35].

2.3. Prediction of Posttranslational Modification (PTM) Sites. Several PTM sites of NcSRS2 protein were predicted, including serine, threonine, and tyrosine phosphorylation sites by NetPhos 3.1 (<http://www.cbs.dtu.dk/services/NetPhos>), palmitoylation or acylation sites by CSS-Palm (<http://csspalm.biocuckoo.org/>), and N-linked and O-linked glycosylation sites by NetNGlyc 1.0 (<http://www.cbs.dtu.dk/services/NetNGlyc/>) and NetOGlyc 4.0 (<http://www.cbs.dtu.dk/services/NetOGlyc/>) web servers. “All Asn residues” option was used for NetNGlyc 1.0 prediction, while default parameters were applied to NetOGlyc 4.0 server.

2.4. Subcellular Localization, Signal Peptide, and Transmembrane Domain Prediction. For the prediction of subcellular localization, DeepLoc 1.0 server was employed, available at <http://www.cbs.dtu.dk/services/DeepLoc/>. For transmembrane domain prediction, TMHMM 2.0 server was used, being available at <http://www.cbs.dtu.dk/services/TMHMM-2.0>. In the following, signal peptide prediction was done using two web servers, including Signal-3L 3.0 (<http://www.csbio.sjtu.edu.cn/bioinf/Signal-3L/>) and SignalP (<http://www.cbs.dtu.dk/services/SignalP/>) web servers.

2.5. Secondary Structure and Disordered Region Prediction. Prediction of the secondary structure was done by the PSI-blast-based secondary structure PREDiction (PSIPRED) server, which is available at <http://bioinf.cs.ucl.ac.uk/psipred/>. This server shows many important features in the submitted protein sequence, if available, such as strand, helix, coil, disordered regions, putative domain boundary, membrane interaction, transmembrane helix, extracellular, reentrant helix, and cytoplasmic and signal peptide in both sequence-based and graphical forms [36].

2.6. Prediction of the Three-Dimensional (3D) Model, Refinement, and Validations. The homology modelling of the NcSRS2 protein was performed using SWISS-MODEL online tool using default parameters (<https://swissmodel.expasy.org/>) [37]. In order to establish likely side chains, repacking them and total refinement of the final structure, the GalaxyRefine server (<http://galaxy.seoklab.org/cgi-bin/submit.cgi?type=REFINE>) was used which provides five refined models for each submitted pdb file, differing on several parameters such as global distance test-high accuracy (GDT-HA), root mean square deviation (RMSD), MolProbability, Clash score, Poor rotamers, and Rama favored [38–40]. Subsequently, the quality improvement of the final structure was evaluated using ProSa-web (Z-score) (<https://prosa.services.came.sbg.ac.at/prosa.php>) [41], ERRAT (quality factor) [42], and PROCHECK (Ramachandran plot analysis) (<https://save.mbi.ucla.edu/>) [43].

2.7. Prediction of Continuous and Conformational B-Cell Epitopes. A multistep approach was exploited for linear B-cell epitope prediction in NcSRS2. For this aim, a fixed-length prediction (14-mer) with 75% specificity was applied in BCPREDS server (<http://ailab.ist.psu.edu/bcpred/predict.html>), which uses subsequent kernel (SSK) and support vector machine (SVM) techniques [44–46]. In the next step, cross-validation of the predicted epitopes was accomplished with the outputs of two other web servers, including ABCpred (http://crdd.osdd.net/raghava/abcpred/ABC_submission) [47] and SVMTriP (<http://sysbio.unl.edu/SVMTriP/prediction.php>) [48]. Those epitopes being shared among outputs of the above servers were selected for further screening regarding antigenicity, allergenicity, and water solubility using VaxiJen v2.0, AllerTOP v2.0, and PepCalc web servers, respectively. Of note, linear B-cell epitopes were, also, predicted by Bcepred server based on different physico-chemical parameters such as hydrophobicity, flexibility, accessibility, turns, exposed surface, polarity, and antigenic propensity (http://crdd.osdd.net/raghava/bcepred/bcepred_submission.html). Additionally, conformational B-cell epitopes were predicted using ElliPro tool of the immune epitope database (IEDB) web server (<http://tools.iedb.org/elliPro/>) [49].

2.8. Prediction and Screening of Mouse Major Histocompatibility- (MHC-) Binding Epitopes. All epitope predictions were done using MHC-I (<http://tools.iedb.org/mhci/>) and MHC-II (<http://tools.immuneepitope.org/mhcii>) binding epitope prediction tools of IEDB server. Regarding MHC-I-binding epitopes, 8 mouse alleles (H2-Db, H2-Dd, H2-Kb, H2-Kd, H2-Kk, H2-Ld, H-2-Qa1, and H-2-Qa2) were used with subsequent screening in terms of antigenicity, allergenicity, and toxicity through VaxiJen v2.0, AllergenFP v1.0, and ToxinPred (<https://webs.iitd.edu.in/raghava/toxinpred/index.html>) servers, respectively. With respect to MHC-II-binding epitopes, 3 mouse alleles (H2-IAb, H2-IAd, and H2-IEd) were employed for epitope prediction, followed by screening regarding antigenicity, allergenicity, toxicity, IFN- γ , and IL-4 induction using VaxiJen v2.0, AllergenFP v1.0, ToxinPred, IFNepitope ([\[webs.iitd.edu.in/raghava/ifnepitope/application.php\]\(https://webs.iitd.edu.in/raghava/ifnepitope/application.php\)\), and IL4-pred \(<https://webs.iitd.edu.in/raghava/il4pred/design.php>\) web servers, correspondingly.](https://</p></div><div data-bbox=)

2.9. Prediction and Screening of Cytotoxic T-Lymphocyte (CTL) Epitopes. Top 10 CTL epitopes of NcSRS2 protein were predicted using CTLpred web server (<https://bio.tools/ctlpred>), followed by screening regarding antigenicity, allergenicity, and hydrophobicity using VaxiJen v2.0, AllergenFP v1.0, and peptide2 (https://www.peptide2.com/N_peptide_hydrophobicity_hydrophilicity.php) web servers, respectively.

3. Results

3.1. General Characteristics of the NcSRS2 Protein. A considerably high antigenic index was predicted for this protein, as substantiated by a VaxiJen score of 0.8286 and ANTIGEN-pro score of 0.966227. Based on the findings from three web servers, no allergenicity, IgE epitopes, and MEME/MAST motifs were found for NcSRS2 protein. High solubility (over 0.45) was, also, predicted by Protein-Sol server with a solubility score of 0.523 (Figure 1). This protein possessed 401 amino acid residues, with a MW of 42009.93 kilo Dalton (kDa) and 45 and 35 negatively (Asp+Glu) and positively charged (Arg+Lys) residues. The extinction coefficients at 280 nm measured in water was 30910 (assuming all pairs form cystines) and 29910 (assuming all Cys residues are reduced) $M^{-1}cm^{-1}$. The estimated half-life was 30 hours in mammalian reticulocytes (in vitro), >20 hours in yeast (in vivo), and >10 hours in *Escherichia coli* (in vivo). The protein was rendered as unstable, since instability index was computed to be 49.24. Moreover, aliphatic index, GRAVY score, and pI of the protein were calculated to be 69.35, -0.294, and 5.28, respectively.

3.2. Prediction of PTM Sites, Subcellular Localization, Transmembrane Domain, and Signal Peptide. In total, 36 phosphorylation sites were present in the NcSRS2 protein using NetPhos server, encompassing 21 serine, 11 tyrosine, and 4 threonine sites. Also, a palmitoylation site at position 6 was found with a score of 36.903 using CSS-Palm server. In addition, NetNGlyc and NetOGlyc web servers predicted 3 and 14 N-glycosylation and O-glycosylation sites in the examined protein, respectively. A putative transmembrane domain was predicted for this protein, as demonstrated by TMHMM server. Outputs of the Signal-3L server (reliability 0.347) and SignalP web tools (Other: 0.6873) showed no traits of a signal peptide in NcSRS2 protein. DeepLoc subcellular localization analysis revealed that NcSRS2 is probably a soluble (likelihood: 0.4508), extracellular protein (likelihood: 0.3435) with membrane localization (likelihood: 0.5492) (Figure 1).

3.3. Secondary Structure Prediction and Disordered Regions. Based on the PSIPRED server analysis with high confidence in most parts, extended strand was the predominant secondary structure in the NcSRS2 protein, followed by helices and coils. Also, 61 residues at N-terminal and 93 residues at C-




FIGURE 1: Computed solubility (a) and subcellular localization (b) of the NcSRS2 protein.

terminal were intrinsically disordered regions in the protein (Figure 2).

3.4. 3D Structure Modelling, Refinement, and Validations.

Two models were built by SWISS-MODEL server, among which a monomer model (template: 2 × 28.1. A) with high coverage and sequence identity of 17.29% was selected for further analysis (Figure 3(a)). This model belonged to sporozoite-specific SAG protein. In the following, GalaxyRefine server provided five models, among which model number five with the following parameters was chosen as the best-fit refined model: GDT-HA: 0.9764, RMSD: 0.352, Mol-Probity: 2.056, Clash score: 22.0, Poor rotamers: 1.4, and Rama favored: 97.5. Finally, the quality of the refined model, as compared with the crude model, was evaluated using three web servers. The Z-score and quality factor of the crude model were -8.07 and 68.493, which were improved to -8.27 and 88.584 after refinement, respectively. The Ramachandran plot analysis of the crude model showed that 82.9%, 15.6%, 1.5%, and 0.0% of residues are assigned to most favored, additional allowed, generously allowed, and disallowed areas, respectively. Upon refinement, they were improved to 90.2%, 8.8%, 0.5%, and 0.5%, correspondingly (Figures 3(b) and 3(c)).

3.5. Linear and Conformational B-Cell Epitopes. A cross-validation method was applied to find shared linear B-cell epitopes. Accordingly, 9 epitopes were found and subsequent screening showed that only two epitopes are potentially antigenic and nonallergenic with good water solubility, including “ECKERPYSAVFPGF” and “GPDGKAFDDY” (Table 1). Moreover, several continuous B-cell epitopes of NcSRS2 protein were determined on the basis of various physicochemical parameters using Bcepred web server (Table 2). Also, ElliPro tool of the IEDB analysis resource demonstrated that there are 4 conformational B-cell epitopes in this protein with the

following lengths and scores: (i) 34 residues, score: 0.713; (ii) 46 residues, score: 0.705; (iii) 42 residues, score: 0.666; and (iv) 16 residues, score: 0.657 (Figure 4).

3.6. Prediction of Mouse MHC-Binding and CTL Epitopes.

For each mouse MHC-I (H2-Db, H2-Dd, H2-Kb, H2-Kd, H2-Kk, H2-Ld, H-2-Qa1, and H-2-Qa2) and MHC-II allele (H2-IAb, H2-IAAd, and H2-IEd), five and six epitopes having the lowest percentile rank (higher affinity) were chosen, respectively, which then subjected to screening in terms of antigenicity, allergenicity, toxicity (MHC-I and MHC-II), and IFN- γ /IL-4 induction (MHC-II). Regarding mouse MHC-I-binding epitopes, seven epitopes had the highest antigenicity score, while they were nonallergenic and nontoxic, including “ITVNPENNGVTL,” “GHPDDKQVTCVV,” “VAHCAYSSNVRL,” “TVNPENNGVTLI,” “SPVLRGDACDEL,” “SAVFPGFSSSFV,” and “KEWVTGTLQQGI” (Table 3). Furthermore, three mouse MHC-II-binding epitopes were capable to induce IFN- γ with high antigenicity and without allergenic and toxic traits, comprising “HCAYSSNVRLRPITV,” “AHCAYSSNVRLRPIT,” and “VAHCAYSSNVRLRPI” (Table 4). Also, top ten CTL epitopes were predicted using CTLpred server, among which 4 epitopes possessed highest antigenicity and hydrophobicity and without allergenicity, encompassing “AYSSNVRLR,” “LRGDACDEL,” “RESEVIGQV,” and “SEDDGLIVC” (Table 5).

4. Discussion

First insights into the immunobiology of the apicomplexan parasite, *N. caninum*, in cattle and dogs were revealed during 1999 to 2003 [18], leading to the initial vaccination approaches in the mouse model [25] as well as cattle as target species [50]. In parallel with the deciphering the parasite biology and identification of parasitic antigens, more




FIGURE 3: NcSRS2 protein homology modelling and refinement validation using the Ramachandran analysis. (a) The final tertiary model of NcSRS2 provided by SWISS-MODEL web server, as shown in ribbon. (b) Ramachandran plot analysis of the crude model using PROCHECK demonstrated that 82.9%, 15.6%, 1.5%, and 0.0% of residues are assigned to most favored, additional allowed, generously allowed, and disallowed areas, respectively. (c) Upon refinement, these parameters were improved to 90.2%, 8.8%, 0.5%, and 0.5%, respectively.

several surface expressed and excretory/secretory proteins have been recognized as vaccine candidates [23, 51–54], while in silico analysis of such proteins and identification of potential immunogenic epitopes was lacking. The present in silico study was performed to highlight several important biochemical properties of the NcSRS2 protein and to identify novel immunogenic epitopes for future vaccination and/or diagnostic purposes in the context of multiepitope protein constructs.

The SRS protein superfamily of *N. caninum* contains about 227 genes and 52 pseudogenes [55, 56], substantially

higher than *Toxoplasma gondii* (*T. gondii*) strains [57]. *Neospora caninum* SAG1 and SRS2 are principal immunodominant surface antigens in tachyzoites, which mediate an initial low-affinity, reversible adhesion to the host cell prior to invasion [23]. Previously, several vaccination studies were done using NcSRS2 alone and/or combined with other parasitic antigens. A satisfactory transplacental protection was obtained upon immunization with recombinant NcSRS2 expressed using a viral vector (vaccinia virus) [25]. The application of NcSRS2 immune-stimulating complexes (ISCOMS) in different formulations reduced the cerebral

TABLE 1: The final screening of shared linear B-cell epitopes from *N. caninum* SRS2.

Shared B-cell epitopes	VaxiJen antigenicity score	AllergenFP allergenicity prediction	PepCalc water solubility prediction
VAKPAGAGSN	1.1244	Yes	Good
ECKERPYSAVFPGF*	1.3682	No	Good
VNRSVSVFA	0.0040	Yes	Poor
VALVYDSQHSIT	0.6158	No	Poor
FSSSFWTGEASGVA	1.2775	No	Poor
KADAACFAKLSASQ	-0.0772	No	Good
GPDGKAFPDDY*	1.6063	No	Good
NNGVTLICGPD	-0.3786	No	Poor
KAGKNVCLL	0.4119	Yes	Good

* indicates antigenic, non-allergenic epitopes with potential good water solubility.

parasite burden and induced specific antibody responses [58, 59]. Mice vaccinated with a set of antigens such as NcGRA6, NcGRA7, NcMIC1, and NcSRS2 expressed in a bacterial vector (*Brucella abortus*) provided complete protection against acute disease [60]. Another study using *N. caninum* cyclophilin-a potent IFN- γ inducer and NcSRS2 showed to be highly efficacious in antibody production and inhibiting cerebral infection [61]. It seems that vaccination with NcSRS2 may play a crucial role in protection against cerebral parasites, though it demands further experimental evidences. Altogether, these findings highlight the importance of NcSRS2 as a promising vaccine candidate. "From a biochemical standpoint, a protein is represented in four structural levels, comprising: (i) amino acid sequences as primary structure, (ii) a native spatial form due to main chain atoms (α -helix and β -fold) as secondary structure, (iii) potential spatial model as a 3D model or tertiary structure, and (iv) number and position of multi-fold subunits in a multi-subunit collection of a protein as quaternary structure" [62–64]. In the first step of this study, we characterized general biochemical features of the protein. It was found that NcSRS2 is a highly antigenic molecule (VaxiJen score: 0.8286, ANTIGENpro: 0.966227), while no allergenic, MEME/MAST motifs and IgE epitopes were found within the sequence; the antigenicity of the NcSRS2 was even higher than the immunodominant molecule, NsSAG1 (VaxiJen score: 0.6278) [65]. High protein solubility was calculated for NcSRS2, with Protein-Sol score of 0.523, similar to NcSAG1 with a solubility of 0.620 [65]. The MW of the NcSRS2 was 42 kDa (those proteins over 5-10 kDa are potent immunogens) [66–68], which is beneficial for SDS-PAGE and western blot analyses. Instability index of over 40 renders the protein to be unstable in vitro, as substantiated by instability score of 49.24. Moreover, this protein was moderately thermotolerant in a wide range of temperatures (aliphatic index: 69.35) and showed to be somehow hydrophilic in nature (GRAVY score: -0.294), contrary to NcSAG1 (GRAVY: 0.031) [65]. The speculated pI for this

protein was estimated as relatively acidic in nature (5.28), being advantageous for purification purposes in ion-exchange chromatography and isoelectric focusing. In contrast, the pI of NsSAG1 protein was estimated as 7.89 [65]. Altogether, such preliminary information may be required for future wet studies using NcSRS2. With 36 regions, phosphorylation was the predominant PTM site in NcSRS2 protein, followed by O-glycosylation (14 regions), N-glycosylation (3 regions), and palmitoylation sites (one region). In total, these PTM regions are crucial in the recombinant production process of the proteins, so that eukaryotic expression systems (yeast, insect, or mammalian) are more preferred in comparison to bacterial hosts [69]. The presence of a signal peptide demonstrates that a synthesized protein could be destined towards several pathways, including excretory-secretory, virulence factor, or surface proteins [70]. Accordingly, based on the results from Signal-3L and SignalP web servers, no signal peptide was present in the sequence. PSIPRED server demonstrated that extended strands are the most prevalent secondary structure in the NcSRS2 protein, followed by helices and coils; inevitably, the protein conformation is maintained and protected during molecular interactions using such internally located structures [71]. Notably, it was found that 61 residues and 93 residues at N-terminal and C-terminal of the sequence are disordered. Disordered proteins are highly abundant, mostly dedicated to regulatory functions and molecular signaling. Supposedly, these regions are likely immunological targets for antibodies; hence, they seem to be important in vaccination studies [72]. For 3D homology modelling, SWISS-MODEL server was employed, which predicted a monomer model with high coverage and 17.29% identity. Actually, the protein possesses a homodimeric form with two domains (D1 and D2) linked by a cysteine bridge (disulfide bonds) as a well-known representative in SRS proteins of *T. gondii* and *N. caninum* [73–76]. Such a marvelous, conserved folding pattern in SRS antigens may be pivotal for their biological function as they potentially couple with sulphated proteoglycan-binding site in target cell receptors [73, 76, 77]. In the following, the 3D model was further subjected to refinement and validations. Based on the ERRAT, ProSa-web, and PROCHECK analyses, it was shown that the quality of the refined model was enhanced after refinement, in comparison with the crude model.

During early *N. caninum* infection, a CD₄⁺ Th1 polarization is a predominant response, leading to IL12-dependent IFN- γ upsurge as a protective immune response [78]. Such specific T-cells are highly vital for protection against the infection in mice. Humoral responses, also, play a critical role in protection mostly biased by IgG2a antibody response in mice. Although cattle is the target species for vaccination studies against neosporosis, mouse models are more accessible and affordable for such purposes [78]. As well, utilization of murine models is a basic step for evaluation of the efficacy of vaccination against neosporosis and toxoplasmosis; accordingly, we premised our immunoinformatics analyses on mouse MHC-I- and MHC-II-binding epitopes. Based on this, several web servers were employed in the present study to accurately predict and screen the potential immunogenic

TABLE 2: Specific B-cell linear epitopes of *N. caninum* SRS2 based on different physicochemical parameters predicted by the Bcepred web server.

Physicochemical parameter	Linear B-cell epitopes
Hydrophilicity	FKSENEKF, PKQGNADQ, ACDGGTP, VCNESDGEDECEKNAA, GCKAGKN, VQSRESEV, TVNPNNGV, CGPDGKA, ELDECKERP, GCTGHPDDKQVTC, GAGSNPGGGSQPDQSSEKRDGEQVNGKGPPTGGSGGAT TGKQNASQNAKDKGETGGENGDSVP, and RGDACDE
Flexibility	LTAKSVN, APFKSEN, IVCNESDGE, NVYVQSRES, ITVNPEN, TELDECK, AVFPGFS, and AGAGSNPGGGSQPDQSSEKRDGEQVNGKGPPTGGSGGATTGKQNASQNAKDKGETGGENG
Accessibility	VVRRKADAA, TAKSVNRS, APFKSENEKFTC, PKQGNADQ, KLLSEDD, NESDGEDECEKNA, LPGAKKEWVTG, TIPDEHYPATSKA, YVQSRESEV, SNVRLRP, TVNPNNGV, KAFPDDYMNHH, TELDECKERPYS AV, LTIPKQDFPST, TGHPDDKQVT, GGSQPDQSSEKRDGEQVNGKGPPTGG, and ATTGKQNASQNAKDKGETGGENGDS
Turns	NPENNGV, DYMNHCTE
Exposed surface	FKSENEKF, EDECEKN, DECKERPYS A, PDQSSEKRDGEQVNGKGPPT, and KQNASQNAKDKGE
Polarity	HACVVRRKADAA, PFKSENEKFTC, KLLSEDD, NESDGEDECEKNAA, P GAKKEWVTG, VQSRESEVIG, DDYMNHHCTELDECKERPYS A, TGHPDDKQV, NIEEVAK, DQSSEKRDGEQVNGK, NAKDKGETG, and RGDACDE
Antigenic propensity	VNRSVSV, LLFGVVLAVGV, FTCLPKQ, LVYDSQH, PLPSKLLS, DDGLIVCNES, PLSTFLP, GKNVCLLNYYVQSRESEVIGQV, NGVTLICGP, QTIYLGCTG, DKQVTCVVPVNI E, and CDELPSY




FIGURE 4: Predicted conformational B-cell epitopes of NcSRS2 using ElliPro tool of IEDB server. Length and score of each epitope were as follows: (1) 34 residues, score: 0.713; (2) 46 residues, score: 0.705; (3) 42 residues, score: 0.666; and (4) 16 residues, score: 0.657.

epitopes in NcSRS2. A multistep approach was conducted to screen linear B-cell epitopes using six web servers, three for identification of shared epitopes (BCPREDS, ABCpred, and SVMTriP) and three for screening phase (VaxiJen, AllerTOP, and PepCalc). Only two epitopes qualified to be a potential immunogenic epitope, including “ECKERPYS AVFPGF” and “GPDGKAFPDDY.” Conformational B-cell epitopes, also, have a remarkable role in the quality of antigen-antibody

interactions. Thereby, we predicted these epitopes in the NcSRS2 protein. The results showed 4 conformational epitopes by the length of 34, 46, 42, and 16 residues, respectively, and qualifying scores of 0.713, 0.705, 0.666, and 0.657. Furthermore, since antigen presentation is highly important for T-cell priming, those epitopes with specific affinity to bind mouse MHC molecules were predicted using IEDB server. With respect to MHC-I-binding epitopes, seven peptides were

TABLE 3: Prediction of mouse MHC-I-binding epitopes of *N. caninum* SRS2 using IEDB server followed by antigenicity, allergenicity, and toxicity screening.

Mouse MHC-I alleles	Position	T-cell peptide	Percentile rank	VaxiJen antigenicity score	AllergenFP allergenicity prediction	ToxinPred toxicity prediction
H2-Db	24-35	ITVNPENNGVTL*	0.61	1.3534	No	Nontoxin
	44-55	VGCKAGKNVCLL	5.4	0.2220	Yes	Toxin
	4-15	YSAVFPGFSSSF	5.4	0.4492	No	Nontoxin
	47-58	KAGKNVCLLNVY	6.7	-0.0962	No	Toxin
	10-21	VAHCAYSSNVRL	7.7	1.5329	No	Nontoxin
H2-Dd	4-15	YSAVFPGFSSSF	0.58	0.4492	No	Nontoxin
	6-17	LSTFLPGAKKEW	4.7	0.0692	Yes	Nontoxin
	48-59	GHPDDKQVTCVV*	4.7	1.7670	No	Nontoxin
	24-35	ITVNPENNGVTL	5.5	1.3534	No	Nontoxin
	26-37	VNPENNGVTLIC	6.7	1.0295	No	Nontoxin
H2-Kb	10-21	VAHCAYSSNVRL*	2.7	1.5329	No	Nontoxin
	31-42	SVNRSVSVFALL	4.0	-0.3061	No	Toxin
	4-15	YSAVFPGFSSSF	5.1	0.4492	No	Nontoxin
	6-17	AVFPGFSSSFWT	7.9	0.8884	No	Nontoxin
	32-43	VNRSVSVFALLF	9.3	0.1617	No	Nontoxin
H2-Kd	24-35	SYVALSAASLTA	2.9	0.4534	No	Nontoxin
	4-15	YSAVFPGFSSSF	6.0	0.4492	No	Nontoxin
	33-44	EHYPATSKAFRV	6.1	0.3313	No	Nontoxin
	33-44	DQFPSTAQTIYL	6.6	-0.0877	No	Toxin
	31-42	PKDQFPSTAQTI	7.0	0.1665	No	Nontoxin
H2-Kk	25-36	TVNPENNGVTLI*	1.4	0.9366	No	Nontoxin
	17-28	DACDELPSYVAL	1.6	0.1381	Yes	Nontoxin
	3-14	ETGGENGDSPVL	3.1	1.1581	Yes	Nontoxin
	33-44	DQFPSTAQTIYL	3.9	-0.0877	No	Toxin
	15-26	KEWVTGTLQQGI	4.9	1.2743	No	Nontoxin
H2-Ld	36-47	LPSKLLSEDDGL	0.42	0.0641	Yes	Nontoxin
	22-33	LPSYVALSAASL	0.92	0.2773	No	Nontoxin
	24-35	ITVNPENNGVTL	1.2	1.3534	No	Nontoxin
	11-22	SPVLRGDACDEL*	1.3	1.3596	No	Nontoxin
	22-33	RPITVNPENNGV	1.7	1.3057	Yes	Nontoxin
H-2-Qa1	4-15	YSAVFPGFSSSF	2.1	0.4492	No	Nontoxin
	17-28	ALVYDSQHSITF	3.3	0.4102	No	Nontoxin
	33-44	VTLICGPDGKAF	5.1	0.4982	Yes	Nontoxin
	24-35	ITVNPENNGVTL	5.4	1.3534	No	Nontoxin
	5-16	SAVFPGFSSSFW*	5.4	1.0065	No	Nontoxin
H-2-Qa2	25-36	TVNPENNGVTLI	2.5	0.9366	No	Nontoxin
	15-26	KEWVTGTLQQGI*	3.1	1.2743	No	Nontoxin
	17-28	ALVYDSQHSITF	3.1	0.4102	No	Nontoxin
	33-44	DQFPSTAQTIYL	4.1	-0.0877	No	Toxin
	3-14	ETGGENGDSPVL	5.3	1.1581	Yes	Nontoxin

* indicates potential high-ranked, antigenic, nonallergenic, and nontoxic epitopes.

shown to be highly antigenic, nonallergenic, and nontoxic, including “ITVNPENNGVTL,” “GHPDDKQVTCVV,” “VAHCAYSSNVRL,” “TVNPENNGVTLI,” “SPVLRGDAC-

DEL,” “SAVFPGFSSSFW,” and “KEWVTGTLQQGI.” Also, three MHC-II-binding peptides “HCAISSNVRLRPITV,” “AHCAISSNVRLRPIT,” and “VAHCAYSSNVRLRPIT” were

TABLE 4: Prediction of mouse MHC-II-binding epitopes of *N. caninum* SRS2 using IEDB server followed by screening for antigenicity, allergenicity, toxicity, and IFN- γ /IL-4 induction.

Mouse MHC-II alleles	Position	T-cell peptide	Percentile rank	VaxiJen antigenicity score	AllergenFP allergenicity prediction	ToxinPred toxicity prediction	IFN- γ induction	IL-4 induction
H2-IAb	23-37	PSYVALSAASLTATA	1.1	0.4796	No	Nontoxin	Positive	Negative
	22-36	LPSYVALSAASLTAT	1.21	0.3898	No	Nontoxin	Positive	Negative
	24-38	SYVALSAASLTATAI	1.41	0.4271	No	Nontoxin	Positive	Negative
	21-35	ELPSYVALSAASLTA	1.5	0.4580	No	Nontoxin	Negative	Negative
	25-39	YVALSAASLTATAIF	1.76	0.3833	No	Nontoxin	Negative	Negative
	2-34	DELPSYVALSAASLT	1.85	0.2164	No	Nontoxin	Negative	Negative
H2-IAd	20-34	DELPSYVALSAASLT	0.64	0.2164	No	Nontoxin	Negative	Negative
	21-35	ELPSYVALSAASLTA	0.73	0.4580	No	Nontoxin	Negative	Negative
	22-36	LPSYVALSAASLTAT	0.73	0.3898	No	Nontoxin	Positive	Negative
	23-37	PSYVALSAASLTATA	0.98	0.4796	No	Nontoxin	Positive	Negative
	24-38	SYVALSAASLTATAI	1.39	0.4271	No	Nontoxin	Positive	Negative
	19-33	CDELPSYVALSAASL	1.59	0.3479	No	Nontoxin	Negative	Positive
H2-IEd	1-15	MATHACVVRKADAA	1.99	-0.3581	No	Nontoxin	Negative	Negative
	2-16	ATHACVVRKADAAC	2.75	-0.5192	Yes	Nontoxin	Negative	Positive
	12-26	HCAYSSNVRLRPITV*	3.00	1.3421	No	Nontoxin	Positive	Negative
	11-25	AHCAYSSNVRLRPIT*	3.35	1.4654	No	Nontoxin	Positive	Negative
	3-17	THACVVRKADAACF	3.9	-0.6533	Yes	Nontoxin	Negative	Positive
	10-24	VAHCAYSSNVRLRPI*	4.1	1.3060	No	Nontoxin	Positive	Negative

* indicates high-ranked, antigenic, and nonallergenic epitopes with potential IFN- γ induction.

TABLE 5: Prediction of top ten cytotoxic T-lymphocyte (CTL) epitopes of *N. caninum* SRS2 using CTLpred web server with antigenicity, allergenicity, and hydrophobicity screening.

Rank	Start position	Peptide sequence	Score (ANN/SVM)	VaxiJen antigenicity score	AllergenFP allergenicity prediction	Hydrophobicity (%)
1	194	AYSSNVRLR*	0.57/1.3921456	1.6339	No	33.33
2	70	GNADQWVAL	0.57/1.1068306	0.4913	No	55.56
3	374	LRGDACDEL*	0.90/0.57070616	1.5932	No	33.33
4	182	RESEVIGQV*	0.61/0.78029309	1.5955	No	33.33
5	228	YMNHHCTEL	0.65/0.73549537	0.4257	No	22.22
6	127	STFLPGAKK	0.93/0.44198631	0.1985	Yes	44.44
7	1	MATHACVVR	0.82/0.53762368	0.0049	No	55.56
8	328	KRDGEQVNK	0.82/0.44522211	1.3420	No	11.11
9	28	TAKSVNRSV	0.61/0.65066346	0.2242	No	33.33
10	102	SEDDGLIVC*	0.65/0.59971526	1.9440	No	33.33

* indicates antigenic, nonallergenic, and hydrophobic CTL epitopes.

potent IFN- γ inducers, highly antigenic epitopes predicted in the context of H2-IEd mouse allele. Previously, Staska et al. [79] showed that residues located at 133-155 of NcSRS2 protein, including most of the above MHC-I and MHC-II epitopes predicted in our study, may represent an epitope cluster, and they are potential IFN- γ inducers in T-lymphocyte cell lines from *N. caninum*-infected cattle [79]. In this sense, a recently published paper demonstrated that NcSRS2 lipopeptides formulated with Freund's adjuvant encompassing amino acids 77 to 95 and 133 to 155 could

robustly induce IFN- γ -secreting T-lymphocytes as well as specific serum antibody responses in immunized cattle [80]. Future vaccinology studies in both mouse and cattle should, therefore, particularly emphasize on this section of the protein. However, other residues also should not be neglected to design more efficacious vaccine candidates. Finally, among the top ten CTL epitopes predicted for NcSRS2 protein in our study, only four "AYSSNVRLR," "LRGDACDEL," "RESEVIGQV," and "SEDDGLIVC" qualified as the potential immunogenic epitopes. Altogether, all of these epitopes could be further

supplied in the multiepitope vaccine constructs and/or diagnostic polypeptides and be evaluated in the context of wet experimental methods.

5. Conclusion

Neospora caninum infection is a global threat to the cattle industry by inflicting reproductive failure and endemic/epidemic abortions. Therefore, there is an increasing need to recognize novel vaccine candidates to be used in the context of unprecedented immunization platforms. The interdisciplinary branch of science, bioinformatics, assist us to characterize the physicochemical features of a protein, to spot highly immunodominant epitopic regions, and to engineer a more rational vaccine design. The apicomplexan SRS proteins are exclusively immunodominant antigens with particular implication in diagnostic tools and/or vaccine candidates. The present in silico study highlighted the most important biophysical characteristics and novel B-cell, MHC-binding, and CTL epitopes of NcSRS2 protein using a set of immunoinformatics servers. This homodimeric protein possesses several potential antigenic epitopes, particularly in 133 to 155 residues, being capable to induce humoral and cellular responses and could be directed towards immunization studies alone or combined with other dominant *N. caninum* antigens.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that there are no conflicts of interest.

References

- [1] J. Ellis, K. Luton, P. R. Baverstock, P. J. Brindley, K. A. Nimmo, and A. M. Johnson, "The phylogeny of *Neospora caninum*," *Molecular and Biochemical Parasitology*, vol. 64, no. 2, pp. 303–311, 1994.
- [2] J. P. Dubey, "Review of *Neospora caninum* and neosporosis in animals," *The Korean Journal of Parasitology*, vol. 41, no. 1, pp. 1–16, 2003.
- [3] E. Javanmardi, H. Majidani, S. A. Shariatzadeh et al., "Global seroprevalence of *Neospora* spp. in horses and donkeys: A systematic review and meta-analysis," *Veterinary Parasitology*, vol. 288, article 109299, 2020.
- [4] J. Dubey and G. Schares, "Neosporosis in animals—The last five years," *Veterinary Parasitology*, vol. 180, no. 1-2, pp. 90–108, 2011.
- [5] M. M. McAllister, J. P. Dubey, D. S. Lindsay, W. R. Jolley, R. A. Wills, and A. M. McGuire, "Rapid communication: dogs are definitive hosts of *Neospora caninum*," *International Journal for Parasitology*, vol. 28, no. 9, pp. 1473–1479, 1998.
- [6] J. S. King, J. Šlapeta, D. J. Jenkins, S. E. Al-Qassab, J. T. Ellis, and P. A. Windsor, "Australian dingoes are definitive hosts of *Neospora caninum*," *International Journal for Parasitology*, vol. 40, no. 8, pp. 945–950, 2010.
- [7] L. F. Gondim, M. M. McAllister, W. C. Pitt, and D. E. Zemlicka, "Coyotes (*Canis latrans*) are definitive hosts of *Neospora caninum*," *International Journal for Parasitology*, vol. 34, no. 2, pp. 159–161, 2004.
- [8] J. Dubey, M. Jenkins, C. Rajendran et al., "Gray wolf (*Canis lupus*) is a natural definitive host for *Neospora caninum*," *Veterinary Parasitology*, vol. 181, no. 2-4, pp. 382–387, 2011.
- [9] M. P. Reichel, M. M. McAllister, A. Nasir, and D. P. Moore, "A review of *Neospora caninum* in water buffalo (*Bubalus bubalis*)," *Veterinary Parasitology*, vol. 212, no. 3-4, pp. 75–79, 2015.
- [10] T. Monney, K. Debache, and A. Hemphill, "Vaccines against a major cause of abortion in cattle, *Neospora caninum* infection," *Animals*, vol. 1, no. 3, pp. 306–325, 2011.
- [11] S. J. Goodswen, P. J. Kennedy, and J. T. Ellis, "A review of the infection, genetics, and evolution of *Neospora caninum*: from the past to the present," *Infection, Genetics and Evolution*, vol. 13, pp. 133–150, 2013.
- [12] S. L. Donahoe, S. A. Lindsay, M. Krockenberger, D. Phalen, and J. Šlapeta, "A review of neosporosis and pathologic findings of *Neospora caninum* infection in wildlife," *International Journal for Parasitology: Parasites and Wildlife*, vol. 4, no. 2, pp. 216–238, 2015.
- [13] J. Dubey, "Neosporosis in cattle: biology and economic impact," *Journal of the American Veterinary Medical Association*, vol. 214, no. 8, pp. 1160–1163, 1999.
- [14] J. Dubey, G. Schares, and L. Ortega-Mora, "Epidemiology and control of neosporosis and *Neospora caninum*," *Clinical Microbiology Reviews*, vol. 20, no. 2, pp. 323–367, 2007.
- [15] J. Dubey and G. Schares, "Diagnosis of bovine neosporosis," *Veterinary Parasitology*, vol. 140, no. 1-2, pp. 1–34, 2006.
- [16] T. Monney and A. Hemphill, "Vaccines against neosporosis: what can we learn from the past studies?," *Experimental Parasitology*, vol. 140, pp. 52–70, 2014.
- [17] S. Kritzner, H. Sager, J. Blum, R. Krebber, G. Greif, and B. Gottstein, "An explorative study to assess the efficacy of toltrazuril-sulfone (ponazuril) in calves experimentally infected with *Neospora caninum*," *Annals of Clinical Microbiology and Antimicrobials*, vol. 1, no. 1, pp. 4–10, 2002.
- [18] M. P. Reichel, L. C. Wahl, and J. T. Ellis, "Research into *Neospora caninum*—what have we learnt in the last thirty years?," *Pathogens*, vol. 9, no. 6, p. 505, 2020.
- [19] A. Hemphill, N. Vonlaufen, and A. Naguleswaran, "Cellular and immunological basis of the host-parasite relationship during infection with *Neospora caninum*," *Parasitology*, vol. 133, no. 3, pp. 261–278, 2006.
- [20] M. P. Reichel and J. T. Ellis, "Neospora caninum—how close are we to development of an efficacious vaccine that prevents abortion in cattle?," *International Journal for Parasitology*, vol. 39, no. 11, pp. 1173–1187, 2009.
- [21] A. Hemphill, K. Debache, T. Monney et al., "Proteins mediating the *Neospora caninum*-host cell interaction as targets for vaccination," *Frontiers in Bioscience (Elite Edition)*, vol. E5, no. 1, pp. 23–36, 2013.
- [22] S. J. Goodswen, P. J. Kennedy, and J. T. Ellis, "Discovering a vaccine against neosporosis using computers: is it feasible?," *Trends in Parasitology*, vol. 30, no. 8, pp. 401–411, 2014.
- [23] A. Cannas, A. Naguleswaran, N. Müller, S. Eperon, B. Gottstein, and A. Hemphill, "Vaccination of mice against experimental *Neospora caninum* infection using NcSAG1-

- and NcSRS2-based recombinant antigens and DNA vaccines,” *Parasitology*, vol. 126, no. 4, pp. 303–312, 2003.
- [24] G. Haldorson, B. Mathison, K. Wenberg et al., “Immunization with native surface protein NcSRS2 induces a Th2 immune response and reduces congenital *Neospora caninum* transmission in mice,” *International Journal for Parasitology*, vol. 35, no. 13, pp. 1407–1415, 2005.
- [25] Y. Nishikawa, X. Xuan, H. Nagasawa et al., “Prevention of vertical transmission of *Neospora caninum* in BALB/c mice by recombinant vaccinia virus carrying NcSRS2 gene,” *Vaccine*, vol. 19, no. 13–14, pp. 1710–1716, 2001.
- [26] A. Asghari, H. Majidiani, M. Fatollahzadeh et al., “Insights into the biochemical features and immunogenic epitopes of common bradyzoite markers of the ubiquitous *Toxoplasma gondii*,” *Infection, Genetics and Evolution*, vol. 95, p. 105037, 2021.
- [27] I. A. Doytchinova and D. R. Flower, “VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines,” *BMC Bioinformatics*, vol. 8, no. 1, pp. 1–7, 2007.
- [28] C. N. Magnan, M. Zeller, M. A. Kayala et al., “High-throughput prediction of protein antigenicity using protein microarray data,” *Bioinformatics*, vol. 26, no. 23, pp. 2936–2943, 2010.
- [29] A. Asghari, H. Nourmohammadi, H. Majidiani, S. A. Shariatzadeh, M. Shams, and F. Montazeri, “In silico analysis and prediction of immunogenic epitopes for pre-erythrocytic proteins of the deadly *Plasmodium falciparum*,” *Infection, Genetics and Evolution*, vol. 93, p. 104985, 2021.
- [30] I. Dimitrov, L. Naneva, I. Doytchinova, and I. Bangov, “AllergenFP: allergenicity prediction by descriptor fingerprints,” *Bioinformatics*, vol. 30, no. 6, pp. 846–851, 2014.
- [31] I. Dimitrov, I. Bangov, D. R. Flower, and I. Doytchinova, “AllerTOP v. 2—a server for in silico prediction of allergens,” *Journal of Molecular Modeling*, vol. 20, no. 6, 2014.
- [32] N. Sharma, S. Patiyal, A. Dhall, A. Pande, C. Arora, and G. P. Raghava, “AlgPred 2.0: an improved method for predicting allergenic proteins and mapping of IgE epitopes,” *Briefings in Bioinformatics*, vol. 22, 2020.
- [33] M. Hebditch, M. A. Carballo-Amador, S. Charonis, R. Curtis, and J. Warwicker, “Protein-Sol: a web tool for predicting protein solubility from sequence,” *Bioinformatics*, vol. 33, no. 19, pp. 3098–3100, 2017.
- [34] A. Asghari, S. Shamsinia, H. Majidiani et al., “Development of a chimeric vaccine candidate based on *Toxoplasma gondii* major surface antigen 1 and apicoplast proteins using comprehensive immunoinformatics approaches,” *European Journal of Pharmaceutical Sciences*, vol. 162, article 105837, 2021.
- [35] E. Gasteiger, C. Hoogland, A. Gattiker, M. R. Wilkins, R. D. Appel, and A. Bairoch, “Protein identification and analysis tools on the ExPASy server,” in *The proteomics protocols handbook*, pp. 571–607, Springer, 2005.
- [36] L. J. McGuffin, K. Bryson, and D. T. Jones, “The PSIPRED protein structure prediction server,” *Bioinformatics*, vol. 16, no. 4, pp. 404–405, 2000.
- [37] M. Biasini, S. Bienert, A. Waterhouse et al., “SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information,” *Nucleic Acids Research*, vol. 42, no. W1, pp. W252–W258, 2014.
- [38] A. D. Ghaffari, A. Dalimi, F. Ghaffarifar, M. Pirestani, and H. Majidiani, “Immunoinformatic analysis of immunogenic B- and T-cell epitopes of MIC4 protein to designing a vaccine candidate against *Toxoplasma gondii* through an in-silico approach,” *Clinical and Experimental Vaccine Research*, vol. 10, no. 1, pp. 59–77, 2021.
- [39] L. Heo, H. Park, and C. Seok, “GalaxyRefine: protein structure refinement driven by side-chain repacking,” *Nucleic Acids Research*, vol. 41, no. W1, pp. W384–W388, 2013.
- [40] M. Shams, E. Javanmardi, M. C. Nosrati et al., “Bioinformatics features and immunogenic epitopes of *Echinococcus granulosus* Myophilin as a promising target for vaccination against cystic echinococcosis,” *Infection, Genetics and Evolution*, vol. 89, p. 104714, 2021.
- [41] M. Wiederstein and M. J. Sippl, “ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins,” *Nucleic Acids Research*, vol. 35, no. Web Server, pp. W407–W410, 2007.
- [42] C. Colovos and T. O. Yeates, “Verification of protein structures: patterns of nonbonded atomic interactions,” *Protein Science*, vol. 2, no. 9, pp. 1511–1519, 1993.
- [43] R. A. Laskowski, M. W. MacArthur, D. S. Moss, and J. M. Thornton, “PROCHECK: a program to check the stereochemical quality of protein structures,” *Journal of Applied Crystallography*, vol. 26, no. 2, pp. 283–291, 1993.
- [44] Y. EL-Manzalawy, D. Dobbs, and V. Honavar, “Predicting linear B-cell epitopes using string kernels,” *Journal of Molecular Recognition*, vol. 21, no. 4, pp. 243–255, 2008.
- [45] H. Majidiani, A. Dalimi, F. Ghaffarifar, M. Pirestani, and A. D. Ghaffari, “Computational probing of *Toxoplasma gondii* major surface antigen 1 (SAG1) for enhanced vaccine design against toxoplasmosis,” *Microbial Pathogenesis*, vol. 147, p. 104386, 2020.
- [46] M. Shams, H. Nourmohammadi, G. Basati, G. Adhami, H. Majidiani, and E. Azizi, “Leishmanolysin gp63: Bioinformatics evidences of immunogenic epitopes in *Leishmania* major for enhanced vaccine design against zoonotic cutaneous leishmaniasis,” *Informatics in Medicine Unlocked*, vol. 24, p. 100626, 2021.
- [47] S. Saha and G. P. S. Raghava, “Prediction of continuous B-cell epitopes in an antigen using recurrent neural network,” *Proteins: Structure, Function, and Bioinformatics*, vol. 65, no. 1, pp. 40–48, 2006.
- [48] B. Yao, L. Zhang, S. Liang, and C. Zhang, “SVMTriP: a method to predict antigenic epitopes using support vector machine to integrate tri-peptide similarity and propensity,” *PLoS One*, vol. 7, no. 9, article e45152, 2012.
- [49] J. Ponomarenko, H.-H. Bui, W. Li et al., “ElliPro: a new structure-based tool for the prediction of antibody epitopes,” *BMC Bioinformatics*, vol. 9, no. 1, p. 514, 2008.
- [50] J. Romero, E. Perez, and K. Frankena, “Effect of a killed whole *Neospora caninum* tachyzoite vaccine on the crude abortion rate of Costa Rican dairy cows under field conditions,” *Veterinary Parasitology*, vol. 123, no. 3–4, pp. 149–159, 2004.
- [51] A. Cannas, A. Naguleswaran, N. Müller, B. Gottstein, and A. Hemphill, “Reduced cerebral infection of *Neospora caninum*-infected mice after vaccination with recombinant microsome protein NcMIC3 and ribi adjuvant,” *Journal of Parasitology*, vol. 89, no. 1, pp. 44–50, 2003.
- [52] X. Cui, T. Lei, D. Yang, P. Hao, and Q. Liu, “Identification and characterization of a novel *Neospora caninum* immune mapped protein 1,” *Parasitology*, vol. 139, no. 8, pp. 998–1004, 2012.
- [53] J. Ellis, C. Miller, H. Quinn, C. Ryce, and M. P. Reichel, “Evaluation of recombinant proteins of *Neospora caninum* as

- vaccine candidates (in a mouse model),” *Vaccine*, vol. 26, no. 47, pp. 5989–5996, 2008.
- [54] W. Li, J. Liu, J. Wang, Y. Fu, H. Nan, and Q. Liu, “Identification and characterization of a microneme protein (NcMIC6) in *Neospora caninum*,” *Parasitology Research*, vol. 114, no. 8, pp. 2893–2902, 2015.
- [55] A. J. Reid, S. J. Vermont, J. A. Cotton et al., “Comparative genomics of the apicomplexan parasites *Toxoplasma gondii* and *Neospora caninum*: *Coccidia* differing in host range and transmission strategy,” *PLoS Pathogens*, vol. 8, no. 3, article e1002567, 2012.
- [56] P. Winzer, J. Müller, D. Imhof et al., “*Neospora caninum*: differential proteome of multinucleated complexes induced by the bumped kinase inhibitor BKI-1294,” *Microorganisms*, vol. 8, no. 6, 2020.
- [57] J. D. Wasmuth, V. Pszeny, S. Haile et al., “Integrated bioinformatic and targeted deletion analyses of the SRS gene superfamily identify SRS29C as a negative regulator of *Toxoplasma* virulence,” *MBio*, vol. 3, no. 6, article e00321, 2012.
- [58] S. Pinitkiatisakul, M. Friedman, M. Wikman et al., “Immunogenicity and protective effect against murine cerebral neosporosis of recombinant NcSRS2 in different iscom formulations,” *Vaccine*, vol. 25, no. 18, pp. 3658–3668, 2007.
- [59] S. Pinitkiatisakul, J. G. Mattsson, M. Wikman et al., “Immunisation of mice against neosporosis with recombinant NcSRS2 iscoms,” *Veterinary Parasitology*, vol. 129, no. 1-2, pp. 25–34, 2005.
- [60] S. Ramamoorthy, N. Sanakkayala, R. Vemulapalli et al., “Prevention of lethal experimental infection of C57BL/6 mice by vaccination with *Brucella abortus* strain RB51 expressing *Neospora caninum* antigens,” *International Journal for Parasitology*, vol. 37, no. 13, pp. 1521–1529, 2007.
- [61] W. Tuo, Y. Zhao, D. Zhu, and M. C. Jenkins, “Immunization of female BALB/c mice with *Neospora cyclophilin* and/or NcSRS2 elicits specific antibody response and prevents against challenge infection by *Neospora caninum*,” *Vaccine*, vol. 29, no. 13, pp. 2392–2399, 2011.
- [62] E. Mahdevar, A. Safavi, A. Abiri et al., “Exploring the cancer-testis antigen BORIS to design a novel multi-epitope vaccine against breast cancer based on immunoinformatics approaches,” *Journal of Biomolecular Structure and Dynamics*, pp. 1–18, 2021.
- [63] H. Nourmohammadi, E. Javanmardi, M. Shams et al., “Multi-epitope vaccine against cystic echinococcosis using immunodominant epitopes from EgA31 and EgG1Y162 antigens,” *Informatics in Medicine Unlocked*, vol. 21, p. 100464, 2020.
- [64] A. Safavi, A. Kefayat, E. Mahdevar, A. Abiri, and F. J. V. Ghahremani, “Exploring the out of sight antigens of SARS-CoV-2 to design a candidate multi-epitope vaccine by utilizing immunoinformatics approaches,” *Vaccine*, vol. 38, pp. 7612–7628, 2020.
- [65] M. Shams, S. Khazaei, N. Nazari, H. Majidiani, and B. Kordi, “Shedding light on biochemical features and potential immunogenic epitopes of *Neospora caninum* SAG1: In silico study,” *Informatics in Medicine Unlocked*, vol. 27, article 100785, 2021.
- [66] M. C. Nosrati, E. Ghasemi, M. Shams et al., “*Toxoplasma gondii* ROP38 protein: bioinformatics analysis for vaccine design improvement against toxoplasmosis,” *Microbial Pathogenesis*, vol. 149, p. 104488, 2020.
- [67] A. Safavi, A. Kefayat, A. Abiri, E. Mahdevar, A. H. Behnia, and F. J. M. I. Ghahremani, “In silico analysis of transmembrane protein 31 (TMEM31) antigen to design novel multi-epitope peptide and DNA cancer vaccines against melanoma,” *Molecular Immunology*, vol. 112, pp. 93–102, 2019.
- [68] A. Safavi, A. Kefayat, F. Sotoodehnejadnematlahi, M. Salehi, and M. H. Modarressi, “In silico analysis of synaptonemal complex protein 1 (SYCP1) and acrosin binding protein (ACRBP) antigens to design novel multi-epitope peptide cancer vaccine against breast cancer,” *International Journal of Peptide Research and Therapeutics*, vol. 25, pp. 1343–1359, 2019.
- [69] M. Rai and H. Padh, “Expression systems for production of heterologous proteins,” *Current Science*, vol. 80, pp. 1121–1128, 2001.
- [70] H. Antelmann, H. Tjalsma, B. Voigt et al., “A proteomic view on genome-based signal peptide predictions,” *Genome Research*, vol. 11, no. 9, pp. 1484–1502, 2001.
- [71] M. Shaddel, M. Ebrahimi, and M. R. Tabandeh, “Bioinformatics analysis of single and multi-hybrid epitopes of GRA-1, GRA-4, GRA-6 and GRA-7 proteins to improve DNA vaccine design against *Toxoplasma gondii*,” *Journal of Parasitic Diseases*, vol. 42, no. 2, pp. 269–276, 2018.
- [72] C. A. MacRaild, J. Seow, S. C. Das, and R. S. Norton, “Disordered epitopes as peptide vaccines,” *Peptide Science*, vol. 110, no. 3, article e24067, 2018.
- [73] X.-L. He, M. E. Grigg, J. C. Boothroyd, and K. C. Garcia, “Structure of the immunodominant surface antigen from the *Toxoplasma gondii* SRS superfamily,” *Nature Structural Biology*, vol. 9, pp. 606–611, 2002.
- [74] D. K. Howe, A. C. Crawford, D. Lindsay, and L. D. Sibley, “The p29 and p35 immunodominant antigens of *Neospora caninum* tachyzoites are homologous to the family of surface antigens of *Toxoplasma gondii*,” *Infection and Immunity*, vol. 66, no. 11, pp. 5322–5328, 1998.
- [75] D. K. Howe and L. D. Sibley, “Comparison of the major antigens of *Neospora caninum* and *Toxoplasma gondii*,” *International Journal for Parasitology*, vol. 29, no. 10, pp. 1489–1496, 1999.
- [76] V. Risco-Castillo, V. Marugan-Hernandez, A. Fernandez-Garcia et al., “Identification of a gene cluster for cell-surface genes of the SRS superfamily in *Neospora caninum* and characterization of the novel SRS9 gene,” *Parasitology*, vol. 138, no. 14, pp. 1832–1842, 2011.
- [77] M. Graille, E. A. Stura, M. Bossus et al., “Crystal Structure of the Complex between the Monomeric Form of *Toxoplasma gondii* Surface Antigen 1 (SAG1) and a Monoclonal Antibody that Mimics the Human Immune Response,” *Journal of Molecular Biology*, vol. 354, no. 2, pp. 447–458, 2005.
- [78] A. Aguado-Martínez, A. P. Basto, A. Leitão, and A. Hemphill, “*Neospora caninum* in non-pregnant and pregnant mouse models: cross-talk between infection and immunity,” *International Journal for Parasitology*, vol. 47, no. 12, pp. 723–735, 2017.
- [79] L. M. Staska, C. J. Davies, W. C. Brown et al., “Identification of vaccine candidate peptides in the NcSRS2 surface protein of *Neospora caninum* by using CD4+ cytotoxic T lymphocytes and gamma interferon-secreting T lymphocytes of infected Holstein cattle,” *Infection and Immunity*, vol. 73, no. 3, pp. 1321–1329, 2005.
- [80] T. V. Baszler, V. Shkap, W. Mwangi et al., “Bovine immune response to inoculation with *Neospora caninum* surface antigen SRS2 lipopeptides mimics immune response to infection with live parasites,” *Clinical and Vaccine Immunology*, vol. 15, no. 4, pp. 659–667, 2008.